Pharma Likelihood Of Approval
We are the trusted, gold standard intelligence provider to the world’s largest industries
GlobalData powers faster, more informed decisions with:
- Granular industry intelligence: We develop deep, vertical-specific intelligence tailored to your industry, providing 360° insight.​
- Exhaustive coverage: We synthesize our vast data universe into formats that support your decision-making needs, covering the sectors, themes, companies and geographies that matter to you. ​
- Proprietary datasets: We provide you with access to untapped pools of intelligence generated from our proprietary datasets and primary research capabilities. ​
- Robust methodologies: The quality and timeliness of our data is a key differentiator. We leverage robust research methodologies to turn millions of data points into trusted intelligence.
Thousands of companies, government organizations, and decision makers rely on GlobalData
We have a track record of serving truly diverse clients, including:
- Corporates: From helping the C-suite refine strategy to powering innovation in marketing and R&D, our corporate use cases are endless. ​
- Investment firms: We help financial analysts develop robust long-term strategies and get alpha signals before the rest. ​
- Professional services: We give consultants, legal, and accounting firms the critical insights to make faster, more informed decisions. ​
- Other sectors: From media to academia, we work with sectors as diverse as our data. ​
The trusted, actionable and future-proof insight you need to stay ahead
We have decades of experience in being the gold standard intelligence provider based on: ​
- Unique data: Proprietary datasets built from terabytes of data. Our unmatched intelligence gives you true strategic advantage.
- Expert analysis: Leverage collective expertise. Count on our extensive team of researchers, analysts, subject matter experts, and journalists, plus thousands of external thought-leaders.​
- Real intelligence over AI: Experience a level of analysis that leaves AI in the dust. Unlock the proprietary datasets unseen by AI and gain a decisive edge. ​
- Time-saving research solutions: Save hundreds of hours on research. Our comprehensive reports let you focus on delivering actionable insights - not searching for them. ​
- Unparalleled global coverage: Tap into insights from anywhere. Our extensive global coverage offers an unrivalled view of the market landscape.​
- One platform: Access all our unique data, expert analysis, and innovative solutions on one platform. ​
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Ivicentamab in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ivicentamab in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Ivicentamab in Chronic Lymphocytic Leukemia (CLL)Drug Details:Ivicentamab (GEN-3009) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Brexanolone in Tinnitus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brexanolone in Tinnitus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brexanolone in Tinnitus Drug Details: Brexanolone (Zulresso) is a mixture of allopregnanolone and...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - DO-1 in GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DO-1 in GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.DO-1 in GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency)Drug Details:DO-1...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Nu-3 in Diabetic Foot Ulcers
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nu-3 in Diabetic Foot Ulcers report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Nu-3 in Diabetic Foot UlcersDrug Details:Nu-3 is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Zalifrelimab in Angiosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zalifrelimab in Angiosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zalifrelimab in Angiosarcoma Drug Details: AGEN-1884 (zalifrelimab) is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Moxidectin in Scabies
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Moxidectin in Scabies report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Moxidectin in ScabiesDrug Details:Moxidectin is a semisynthetic derivative of nemadectin and acts as an...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Tofacitinib Citrate in Chronic Granulomatous Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tofacitinib Citrate in Chronic Granulomatous Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Tofacitinib Citrate in Chronic Granulomatous DiseaseDrug Details: Tofacitinib (Xeljanz, Jaquinus) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Ozempic in Liver Cirrhosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ozempic in Liver Cirrhosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ozempic in Liver Cirrhosis Drug Details: Semaglutide (Ozempic / NN-9535 / NN-9931)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Ozempic in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ozempic in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ozempic in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Semaglutide (Ozempic / NN-9535...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Verdiperstat in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Verdiperstat in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Verdiperstat in Multiple...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.